Loading
TB
Translate Bio, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Sanofi, was filed 14 Sept 2021.
Translate Bio, Inc.: what insiders have been doing
Translate Bio, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). The past year has been quiet: not a single insider filing for Translate Bio, Inc. The previous disclosure was published on 16 September 2021.
Looking back to 2018, when coverage begins, insiders filed 6 purchases and 18 sales.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and EssilorLuxottica. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
46
Thresholds
n/a
Buy Volume
€2B
6 ops. · all time
Sell Volume
€234M
18 ops. · all time
Since the insiders bought
- -83.4%Entry US$229.86 · Close at T+365 US$38.16
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
US$0.04
Analyst consensus
Income statement
RevenueUS$27.5M
Gross profitUS$17M62% margin
EBITDA-US$40.5M-147% margin
Net income-US$49M-267.4% margin
Valuation
Beta2.58
Balance sheet & cash
Total debtUS$34.4M
Free Cash Flow-US$36.6M
Debt / Equity421%
Profitability & ownership
ROE-179.0%
ROA-30.1%
% institutions0.0%
Last declaration on 16 September 2021
Declarations46 total
18,044,239 shares@ €32.189850.0% of flowCommon StockSEC:0001567619-21-017206:0
409,913 shares@ US$38.00Common StockSEC:0001209191-21-056062:1
40,909 shares@ US$38.00Common StockSEC:0001209191-21-056062:2
20,515,985 shares@ US$38.00Common Stock, par value $0.001 per shareSEC:0000899243-21-035757:1
Canonical exit: 13 Dec 2021 (T+90)
51,467,612 shares@ US$38.00100.0% of flowCommon Stock, par value $0.001 per shareSEC:0000899243-21-035757:0
Canonical exit: 13 Dec 2021 (T+90)
2,055,063 shares@ US$38.00100.0% of flowCommon StockSEC:0001209191-21-056045:0
71,833 shares@ US$38.00100.0% of flowCommon StockSEC:0001209191-21-056057:0
29,860 shares@ US$38.00100.0% of flowCommon StockSEC:0001209191-21-056049:0
503,231 shares@ US$38.0099.7% of flowCommon StockSEC:0001209191-21-056062:0
9,026 shares@ US$7.39Common StockSEC:0001209191-21-026217:0
5,638 shares@ US$7.39Common StockSEC:0001209191-21-003697:0
1 shares@ US$8.34Common StockSEC:0001209191-21-003697:1
2,700 shares@ US$0.00960.0% of flowCommon StockSEC:0001104659-20-139273:2
56,536 shares@ US$25.5046Common StockSEC:0001104659-20-139273:0
79,865 shares@ US$25.0421Common StockSEC:0001104659-20-139273:1
53,004 shares@ US$7.39Common StockSEC:0001209191-20-059255:0
3 shares@ US$8.34Common StockSEC:0001209191-20-059255:1
34,410 shares@ US$15.00Common StockSEC:0001104659-20-099718:0
44,381 shares@ US$14.80Common StockSEC:0001104659-20-099718:1
10,097 shares@ US$14.38Common StockSEC:0001104659-20-099718:2
6,824,992 shares@ US$20.68Common StockSEC:0001395064-20-000122:0
500,000 shares@ US$22.00Common StockSEC:0001567619-20-012703:0
Canonical exit: 24 Sept 2020 (T+90)
40,086 shares@ US$19.75Common StockSEC:0001395064-20-000084:0
107,072 shares@ US$19.85Common StockSEC:0001395064-20-000082:0
100,389 shares@ US$19.75Common StockSEC:0001395064-20-000082:2
25 of 46 declarations
About Translate Bio, Inc.
Translate Bio, Inc. was a U.S.-based biopharmaceutical company focused on messenger RNA (mRNA) therapeutics and vaccines. It was listed in the United States on the NASDAQ under ticker TBIO, and its historical operational base was in Lexington, Massachusetts. For investors, the company fit squarely into the high-risk, high-science segment of biotech: it was a clinical-stage developer rather than a commercial drug maker, with value creation driven primarily by research progress, partnership milestones, and regulatory execution. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1693415/000120919121056057/0001209191-21-056057-index.htm?utm_source=openai))
Translate Bio was built around a differentiated mRNA platform intended to address diseases caused by protein or gene dysfunction and to prevent infectious diseases by generating protective immunity. The company reached public markets through its IPO in 2018, after which its filings consistently described it as a clinical-stage mRNA therapeutics business. That positioning made it a specialized player in a field that attracted increasing investor attention as mRNA became one of the most important technological themes in modern biotech. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1693415/000156459019008803/tbio-10k_20181231.htm?utm_source=openai))
Read moreShow less
Its core business lines were centered on two broad areas: therapeutic programs and vaccine programs based on mRNA. In practice, the company’s most important strategic partnership was with Sanofi, which supported development efforts across selected programs. This type of collaboration-based model is common in emerging biotech: it reduces the burden of standalone commercialization, but it also means the company’s valuation is highly sensitive to clinical data, partner commitment, and the ability to advance assets toward proof of concept. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1693415/000119312521247021/d117934dsc14d9.htm?utm_source=openai))
From a competitive standpoint, Translate Bio occupied a niche within the mRNA ecosystem. Compared with large pharmaceutical companies, it lacked scale and commercial breadth, but it had scientific focus and platform purity. For equity analysts, the key questions were whether the platform could generate clinically meaningful data, whether the partnership with Sanofi could unlock broader pipeline value, and whether the company could translate research momentum into durable economic returns. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1693415/000119312521234062/d191890dex993.htm?utm_source=openai))
A major recent development was Sanofi’s acquisition of Translate Bio in 2021. Sanofi announced the definitive agreement in August 2021 and later completed the acquisition in September 2021, effectively ending Translate Bio’s life as an independent public company. That fact matters materially for current market context: although historical SEC Form 4 insider transactions may still exist, TBIO is no longer an ongoing standalone listed equity story. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1693415/000119312521234062/d191890dex993.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
